Activating the tumor-associated immune system with an siRNA conjugated to a Toll-like receptor 9 ligand is a promising anticancer strategy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Aouadi, M. et al. Nature 458, 1180–1184 (2009).
MacDiarmid, J.A. et al. Nat. Biotechnol. 27, 643–651 (2009).
Peer, D. et al. Science 319, 627–630 (2008).
Poeck, H. et al. Nat. Med. 14, 1256–1263 (2008).
Sato, Y. et al. Nat. Biotechnol. 26, 431–442 (2008).
Kortylewski, M. et al. Nat. Biotechnol. 27, 925–932 (2009).
Marques, J.T. & Williams, B.R. Nat. Biotechnol. 23, 1399–1405 (2005).
Kleinman, M.E. et al. Nature 452, 591–597 (2008).
Kortylewski, M. et al. Nat. Med. 11, 1314–1321 (2005).
McNamara, J.O. II et al. Nat. Biotechnol. 24, 1005–1015 (2006).
MacDiarmid, J.A. et al. Cancer Cell 11, 431–445 (2007).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gantier, M., Williams, B. siRNA delivery not Toll-free. Nat Biotechnol 27, 911–912 (2009). https://doi.org/10.1038/nbt1009-911
Issue Date:
DOI: https://doi.org/10.1038/nbt1009-911
This article is cited by
-
Rational Design of Immunostimulatory siRNAs
Molecular Therapy (2010)